NCT02246816View on ClinicalTrials.gov

A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Short Bowel SyndromeShort Gut SyndromeSBSShort Gut
Interventions
DRUG

0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)

0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)

Trial Locations (5)

44195

Cleveland Clinic, Cleveland

45801

Regional Infectious Disease Infusion Center, Lima

46202

Indiana University, Indianapolis

60611

Northwestern University Feinberg School of Medicine, Chicago

37212-1150

Vanderbilt Center for Human Nutrition, Nashville

Sponsors
All Listed Sponsors
lead

Marathon Pharmaceuticals, LLC

INDUSTRY